Twice-Daily Dolutegravir-Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention.

Journal:

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Volume: 79, Issue: 4

Published:

October 15, 2024

PMID:

38568956

Authors:

Anthony T Podany AT, Yoninah Cramer Y, Marjorie Imperial M, Susan L Rosenkranz SL, Anchalee Avihingsanon A, Roberto Arduino R, Wadzanai Samaneka W, Irina Gelmanova I, Rada Savic R, Susan Swindells S, Rodney Dawson R, Anne F Luetkemeyer AF

Access Paper

DOI: 10.1093/cid/ciae183

PMID: 38568956

Abstract:

One month of daily rifapentine + isoniazid (1HP) is an effective, ultrashort option for tuberculosis prevention in people with human immunodeficiency virus (HIV). However, rifapentine may decrease antiretroviral drug concentrations and increase the risk of virologic failure. AIDS Clinical Trials Group A5372 evaluated the effect of 1HP on the pharmacokinetics of twice-daily dolutegravir.

Courtesy of the U.S. National Library of Medicine